Diplomat Pharmacy (DPLO) Misses Q3 EPS by 3c, Offers Guidance
Get Alerts DPLO Hot Sheet
Join SI Premium – FREE
Diplomat Pharmacy (NYSE: DPLO) reported Q3 EPS of $0.21, $0.03 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $1.18 billion versus the consensus estimate of $1.26 billion.
GUIDANCE:
Diplomat Pharmacy sees FY2016 EPS of $0.83-$0.87, versus the consensus of $0.93. Diplomat Pharmacy sees FY2016 revenue of $4.4-4.6 billion, versus the consensus of $4.67 billion.
For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- PTC Therapeutics (PTCT) Tops Q1 EPS by 9c, provides guidance
- USCB Financial Holdings, Inc. (USCB) Tops Q1 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!